Hrt Financial adds Pfizer (PFE) to its portfolio

Pfizer (PFE) : Hrt Financial added new position in Pfizer during the most recent quarter end. The investment management firm now holds 24,121 shares of Pfizer which is valued at $843,753 , the company said in a statement filed on Aug 10, 2016 with the SEC.Pfizer makes up approximately 0.49% of Hrt Financial’s portfolio.

Other Hedge Funds, Including , Cabot-wellington reduced its stake in PFE by selling 3,000 shares or 25.0% in the most recent quarter. The Hedge Fund company now holds 9,000 shares of PFE which is valued at $316,350. Pfizer makes up approx 0.27% of Cabot-wellington’s portfolio.Signalpoint Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 15,837 shares of Pfizer which is valued at $584,227. Pfizer makes up approx 0.24% of Signalpoint Asset Management’s portfolio.Louisiana State Employees Retirement System reduced its stake in PFE by selling 6,600 shares or 1.63% in the most recent quarter. The Hedge Fund company now holds 397,900 shares of PFE which is valued at $14,662,615. Pfizer makes up approx 0.75% of Louisiana State Employees Retirement System’s portfolio.James Investment Research Inc boosted its stake in PFE in the latest quarter, The investment management firm added 78,384 additional shares and now holds a total of 878,186 shares of Pfizer which is valued at $32,176,735. Pfizer makes up approx 0.79% of James Investment Research Inc’s portfolio.

Pfizer closed down -0.21 points or -0.60% at $34.98 with 1,95,68,121 shares getting traded on Friday. Post opening the session at $35.06, the shares hit an intraday low of $34.825 and an intraday high of $35.12 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.